124 related articles for article (PubMed ID: 9892985)
1. p53 protein overexpression and gene mutation in mixed Müllerian tumors of the uterus.
Soong R; Knowles S; Hammond IG; Michael C; Iacopetta BJ
Cancer Detect Prev; 1999; 23(1):8-12. PubMed ID: 9892985
[TBL] [Abstract][Full Text] [Related]
2. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components.
Kounelis S; Jones MW; Papadaki H; Bakker A; Swalsky P; Finkelstein SD
Hum Pathol; 1998 Jan; 29(1):82-7. PubMed ID: 9445138
[TBL] [Abstract][Full Text] [Related]
3. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT.
Rushing RS; Shajahan S; Chendil D; Wilder JL; Pulliam J; Lee EY; Ueland FR; van Nagell JR; Ahmed MM; Lele SM
Gynecol Oncol; 2003 Oct; 91(1):9-14. PubMed ID: 14529657
[TBL] [Abstract][Full Text] [Related]
4. p53 immunoreactivity and mutation of the p53 gene in smooth muscle tumours of the uterine corpus.
Jeffers MD; Farquharson MA; Richmond JA; McNicol AM
J Pathol; 1995 Sep; 177(1):65-70. PubMed ID: 7472782
[TBL] [Abstract][Full Text] [Related]
5. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
[TBL] [Abstract][Full Text] [Related]
6. Nuclear overexpression of p53 protein does not correlate with gene mutation in primary peritoneal carcinoma.
Marchenko ND; Moll UM
Hum Pathol; 1997 Sep; 28(9):1002-6. PubMed ID: 9308722
[TBL] [Abstract][Full Text] [Related]
7. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes.
Tsuda H; Hirohashi S
Jpn J Cancer Res; 1992 Nov; 83(11):1184-91. PubMed ID: 1336492
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis.
Jin Z; Ogata S; Tamura G; Katayama Y; Fukase M; Yajima M; Motoyama T
Int J Gynecol Pathol; 2003 Oct; 22(4):368-73. PubMed ID: 14501818
[TBL] [Abstract][Full Text] [Related]
9. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours.
Abeln EC; Smit VT; Wessels JW; de Leeuw WJ; Cornelisse CJ; Fleuren GJ
J Pathol; 1997 Dec; 183(4):424-31. PubMed ID: 9496259
[TBL] [Abstract][Full Text] [Related]
10. p53 alterations are associated with improved prognosis in distal colonic carcinomas.
Soong R; Grieu F; Robbins P; Dix B; Chen D; Parsons R; House A; Iacopetta B
Clin Cancer Res; 1997 Aug; 3(8):1405-11. PubMed ID: 9815825
[TBL] [Abstract][Full Text] [Related]
11. Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India.
Karim S; Ali A
World J Gastroenterol; 2009 Mar; 15(11):1381-7. PubMed ID: 19294769
[TBL] [Abstract][Full Text] [Related]
12. Proliferation indices and p53-immunocytochemistry in uterine mixed mullerian tumors.
Nicòtina PA; Ferlazzo G; Vincelli AM
Histol Histopathol; 1997 Oct; 12(4):967-72. PubMed ID: 9302556
[TBL] [Abstract][Full Text] [Related]
13. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutation in relation to p53 protein accumulation in male and female breast cancer.
Nayak BK; Baral RN; Das BR
Neoplasma; 1996; 43(5):305-10. PubMed ID: 8996549
[TBL] [Abstract][Full Text] [Related]
15. Comparative survival analysis of p53 gene mutations and protein accumulation in colorectal cancer.
Caldes T; Iniesta P; Vega FJ; de Juan C; Lopez JA; Diaz-Rubio E; Fernandez C; Cerdan J; Balibrea JL; Benito M
Oncology; 1998; 55(3):249-57. PubMed ID: 9560058
[TBL] [Abstract][Full Text] [Related]
16. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
17. Expression and mutation of the tumor suppressor gene p53 in AIDS-associated Kaposi's sarcoma.
Li JJ; Huang YQ; Cockerell CJ; Zhang WG; Nicolaides A; Friedman-Kien AE
Am J Dermatopathol; 1997 Aug; 19(4):373-8. PubMed ID: 9261472
[TBL] [Abstract][Full Text] [Related]
18. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
19. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics.
Kernochan LE; Garcia RL
J Natl Compr Canc Netw; 2009 May; 7(5):550-6; quiz 557. PubMed ID: 19460280
[TBL] [Abstract][Full Text] [Related]
20. Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry.
Schneider J; Rubio MP; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
Eur J Cancer; 1994; 30A(4):504-8. PubMed ID: 8018409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
